Radiopharm Theranostics Ltd
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Radiopharm Theranostics has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Radiopharm Theranostics filed with the SEC
RAD COMPLETES MEETING WITH US FDA FOR DEVELOPMENT OF RAD101
EX-99.1 to Form 6-K
CHANGE OF DIRECTOR'S INTEREST NOTICE (RC)
EX-99.1 to Form 6-K
NOTIFICATION OF CESSATION OF SECURITIES - RAD
EX-99.2 to Form 6-K
APPENDIX 4G AND CORPORATE GOVERNANCE STATEMENT
EX-99.1 to Form 6-K
CHANGE OF DIRECTOR'S INTEREST NOTICES X 4
EX-99.1 to Form 6-K
RAD ORAL PRESENTATION AT SNO26 ON RAD101 PHASE IIB DATA
EX-99.1 to Form 6-K
RAD ANNOUNCES POSITIVE DATA FROM RAD301 P1 IMAGING TRIAL
EX-99.1 to Form 6-K
APPENDIX 4E AND PRELIMINARY FINAL REPORT
EX-99.1 to Form 6-K
CHANGE OF DIRECTOR'S INTEREST NOTICES X 4
EX-99.1 to Form 6-K
RAD DOSES FIRST PATIENT IN SECOND COHORT OF BETABART (RV-01)
EX-99.1 to Form 6-K
RAD ADVANCES TO COHORT 4 IN 177LU-RAD202 PHASE 1 HEAT TRIAL
EX-99.1 to Form 6-K
RAD TO MEET WITH US FDA TO ALIGN ON RAD 101 PHASE 3 TRIAL
EX-99.1 to Form 6-K
NOTICE OF EXTRAORDINARY GENERAL MEETING AND PROXY FORM
EX-99.1 to Form 6-K
APPLICATION FOR QUOTATION OF SECURITIES - RAD
EX-99.1 to Form 6-K
QUARTERLY ACTIVITIES/APPENDIX 4C CASH FLOW REPORT
EX-99.1 to Form 6-K
APPLICATION FOR QUOTATION OF SECURITIES - RAD
EX-99.1 to Form 6-K
Notice Under Section 708A(5)(e) of the Corporations
EX-99.2 to Form 6-K
PRESS RELEASE DATED JULY 24, 2026
EX-99.1 to Form 6-K
RAD ACHIEVES PARTIAL RESPONSE IN PHASE 1 TRIAL OF RAD204
EX-99.1 to Form 6-K
RAD ANNOUNCES POSITIVE PHASE 2B TRIAL RESULTS OF RAD 101
EX-99.2 to Form 6-K
RADIOPHARM RECEIVES $5.9M R&D TAX INCENTIVE
EX-99.1 to Form 6-K
NOTIFICATION OF CESSATION OF SECURITIES - RAD
EX-99.1 to Form 6-K
NOTIFICATION REGARDING UNQUOTED SECURITIES - RAD
EX-99.2 to Form 6-K
NOTIFICATION OF CESSATION OF SECURITIES - RAD
EX-99.1 to Form 6-K
FINANCIAL SERVICES AND COMPANY SECRETARY CHANGES
EX-99.1 to Form 6-K
QUARTERLY ACTIVITIES/APPENDIX 4C CASH FLOW REPORT
EX-99.1 to Form 6-K
RAD INITIAL FINDINGS FROM PHASE 1 177LU-RAD202 TRIAL
EX-99.1 to Form 6-K
RAD COMPLETES ENROLLMENT IN PHASE 2B TRIAL OF RAD 101
EX-99.1 to Form 6-K
RAD202 PHASE 1 HEAT TRIAL ADVANCES TO DOSE LEVEL 3
EX-99.1 to Form 6-K
RAD AND SIEMENS SIGN CLINICAL SUPPLY AGREEMENT FOR RAD101
EX-99.1 to Form 6-K
RAD DOSES FIRST PATIENT IN RAD 402 PHASE 1 CLINICAL STUDY
EX-99.1 to Form 6-K
RAD101 2ND INTERIM PH.2B DATA - 90% ACHIEVE PRIMARY ENDPOINT
EX-99.1 to Form 6-K
RAD TO PRESENT AT NWR VIRTUAL HEALTHCARE CONFERENCE
EX-99.1 to Form 6-K
HALF YEAR REPORT AND APPENDIX 4D 31 DECEMBER 2025
EX-99.1 to Form 6-K
RAD DOSES FIRST PATIENT IN 177LU-BETABART (RV-01) STUDY
EX-99.1 to Form 6-K
QUARTERLY ACTIVITIES/APPENDIX 4C CASH FLOW REPORT
EX-99.1 to Form 6-K
RAD INCREASES OWNERSHIP IN RADIOPHARM VENTURES TO 87.5%
EX-99.1 to Form 6-K